TGFBR2 and myeloid sarcoma: Moreover, the analysis of TGFBR2 expression ex vivo revealed a significant downregulation of TGFBR2 expression in RRMS patients compared to HVs (Figure 4(b)), reflecting a possible direct association with the reported miR-17 upregulation in MS.